Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Among persons with breast cancer previously treated with hormonal therapy, the AKT pathway inhibitor capivasertib when added to fulvestrant significantly prolonged progression-free survival as compared with fulvestrant alone.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-06, Vol.388 (22), p.2058-2070
Hauptverfasser:	Turner, Nicholas C., Oliveira, Mafalda, Howell, Sacha J., Dalenc, Florence, Cortes, Javier, Gomez Moreno, Henry L., Hu, Xichun, Jhaveri, Komal, Krivorotko, Petr, Loibl, Sibylle, Morales Murillo, Serafin, Okera, Meena, Park, Yeon Hee, Sohn, Joohyuk, Toi, Masakazu, Tokunaga, Eriko, Yousef, Samih, Zhukova, Lyudmila, de Bruin, Elza C., Grinsted, Lynda, Schiavon, Gaia, Foxley, Andrew, Rugo, Hope S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events AKT protein AKT1 protein Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aromatase Aromatase Inhibitors - adverse effects Aromatase Inhibitors - therapeutic use Breast Cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer therapies Cyclin-dependent kinase 4 Cyclin-dependent kinases Diarrhea Disease prevention Double-Blind Method Double-blind studies Endocrine therapy Estrogens Female Fulvestrant Fulvestrant - adverse effects Fulvestrant - therapeutic use Hematology Humans Kinases Magnetic resonance imaging Male Metastasis Mutation Neoplasm Recurrence, Local - drug therapy Oncology Placebos Post-menopause Proto-Oncogene Proteins c-akt PTEN protein Quality of life Receptor, ErbB-2 Regulatory approval Survival Treatments in Oncology Tumors Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Among persons with breast cancer previously treated with hormonal therapy, the AKT pathway inhibitor capivasertib when added to fulvestrant significantly prolonged progression-free survival as compared with fulvestrant alone.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2214131